menu
    • menu
    [{"orgOrder":0,"company":"Heat Biologics","sponsor":"Heat Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"gp-96 based COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Heat Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Heat Biologics"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"T Cell","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Nivolumab","moa":"T-Cell mediated immune response","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PTX-35","moa":"TNFRSF25","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"PTX-35","moa":"TNFRSF25","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"HS-130","moa":"T-Cell mediated immune response","graph1":"Oncology","graph2":"Phase I","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Elusys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Heat Biologics \/ Heat Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Heat Biologics \/ Heat Biologics"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Erlotinib","moa":"HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Elusys Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Obiltoxaximab","moa":"Bacillus protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Heat Biologics \/ Heat Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Heat Biologics \/ Heat Biologics"}]

    Find Clinical Drug Pipeline Developments & Deals by Heat Biologics

    Menu

    Heat Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Elusys Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heat Biologics (NightHawk Biosciences) Completes Acquisition of Elusys Therapeutics

                            Details : Pursuant to this acquisition, NightHawk announced it plans to migrate manufacturing of ANTHIM® to its planned Scorpion biomanufacturing facility in Manhattan, Kansas, which is being constructed to support development of commercial-scale biologics and la...

                            Brand Name : Anthim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 20, 2022

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Elusys Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viagenpumatucel-L,Erlotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

                            Details : New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.

                            Brand Name : HS-110

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            March 25, 2022

                            Lead Product(s) : Viagenpumatucel-L,Erlotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Elusys Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

                            Details : The strategic acquisition of Elusys is intended to enhance Heat’s immunotherapy portfolio and further position Heat to take a lead role in the biodefense space. The addition of ANTHIM (obiltoxaximab) Injection, together with Heat’s previously announc...

                            Brand Name : Anthim

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 21, 2021

                            Lead Product(s) : Obiltoxaximab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Elusys Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator

                            Details : The patent covers compositions of matter that are part of Heat's gp96 platform (antigen presentation, T cell activation, TLR activation) in combination with Inducible T cell Co-stimulator (ICOS) ligand or ICOSL, a T cell immune booster, in a single thera...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 07, 2020

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viagenpumatucel-L,HS-130,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Issued Key Patent on Combination Platform Therapy

                            Details : Heat Biologics been issued a patent (US Patent No. 10,758,611) by the U.S. Patent and Trademark Office (USPTO) covering compositions of matter that are part of Heat's gp96 platform in combination with a T cell costimulatory agonist in a single therapy.

                            Brand Name : HS-110

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 02, 2020

                            Lead Product(s) : Viagenpumatucel-L,HS-130,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Highlights Importance of T cell Immunity to Prevent COVID-19

                            Details : Heat's COVID-19 vaccine is designed to drive T cell immunity, while also activating antibody responses and innate immunity, which may complement conventional COVID-19 vaccines in combination approaches by enhancing T cell immunity.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 05, 2020

                            Lead Product(s) : COVID-19 vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-35

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35

                            Details : First patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary.

                            Brand Name : PTX-35

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 22, 2020

                            Lead Product(s) : PTX-35

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PTX-35

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Announces FDA Clearance of Investigational New Drug (IND) Application for PTX-35

                            Details : Preclinical studies have demonstrated PTX-35, in combination with antigen-driven immunotherapies, resulted in enhanced anti-tumor properties, including potent proliferation of antigen-specific T cells, production of effector cytokines and augmented effec...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 08, 2020

                            Lead Product(s) : PTX-35

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viagenpumatucel-L,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for Presentation at 2020 ASCO Annual Meeting

                            Details : Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 14, 2020

                            Lead Product(s) : Viagenpumatucel-L,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Heat Biologics

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Viagenpumatucel-L,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Heat Biologics Reports Continued Progress Advancing HS-110

                            Details : Heat Biologics continue to make good progress on its clinical-stage portfolio, as well as its COVID-19 vaccine platform, and look forward to presenting additional HS-110 data on May 29 at ASCO.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 11, 2020

                            Lead Product(s) : Viagenpumatucel-L,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth